期刊
RESPIROLOGY
卷 16, 期 7, 页码 1088-1095出版社
WILEY
DOI: 10.1111/j.1440-1843.2011.02018.x
关键词
adrenal insufficiency; hydrocortisone; mortality; septic shock; shock reversal
Background and objective: Although there is controversy regarding the benefit of low-dose corticosteroid therapy in patients with septic shock, the Surviving Sepsis Campaign has advocated that low-dose intravenous hydrocortisone be used to treat adult septic shock patients. This study investigated the effect of the duration of a stress dose of hydrocortisone on survival of septic shock patients with relative adrenal insufficiency. Methods: One hundred and thirty consecutive patients who met the American College of Chest Physicians/Society of Critical Care Medicine criteria for septic shock were included in the study. An additional inclusion criterion was vasopressor support after fluid resuscitation. The primary end-point was 28-day mortality, and the secondary end-points were shock reversal and mortality in the intensive care unit and hospital. All eligible patients were prospectively randomized to receive hydrocortisone treatment for 3 or 7 days. Hydrocortisone treatment was started at a dose of 50 mg every 6 h. Results: Baseline data at recruitment did not differ between the two groups. After 28 days, mortality did not differ between the 3- and 7-day treatment groups (33.8% vs 36.9%, P = 0.629). Mortality rates in the intensive care unit and hospital did not differ significantly between the two groups. The median time to withdrawal of vasopressor therapy was 5.0 days in the 3-day treatment group and 6.4 days in the 7-day treatment group (P = 0.102). Conclusions: This pilot study showed that in patients with septic shock and relative adrenal insufficiency, 28-day mortality did not differ between those treated with low-dose hydrocortisone for 3 or 7 days.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据